Modulation of fracture healing by senescence-associated secretory phenotype (SASP): a narrative review of the current literature

Eur J Med Res. 2024 Jan 9;29(1):38. doi: 10.1186/s40001-023-01604-7.

Abstract

The senescence-associated secretory phenotype (SASP) is a generic term for the secretion of cytokines, such as pro-inflammatory factors and proteases. It is a crucial feature of senescent cells. SASP factors induce tissue remodeling and immune cell recruitment. Previous studies have focused on the beneficial role of SASP during embryonic development, wound healing, tissue healing in general, immunoregulation properties, and cancer. However, some recent studies have identified several negative effects of SASP on fracture healing. Senolytics is a drug that selectively eliminates senescent cells. Senolytics can inhibit the function of senescent cells and SASP, which has been found to have positive effects on a variety of aging-related diseases. At the same time, recent data suggest that removing senescent cells may promote fracture healing. Here, we reviewed the latest research progress about SASP and illustrated the inflammatory response and the influence of SASP on fracture healing. This review aims to understand the role of SASP in fracture healing, aiming to provide an important clinical prevention and treatment strategy for fracture. Clinical trials of some senolytics agents are underway and are expected to clarify the effectiveness of their targeted therapy in the clinic in the future. Meanwhile, the adverse effects of this treatment method still need further study.

Keywords: Bone; Fracture healing; SASP; Senescence; Senolytics.

Publication types

  • Review

MeSH terms

  • Cytokines
  • Female
  • Fracture Healing*
  • Fractures, Bone*
  • Humans
  • Pregnancy
  • Senescence-Associated Secretory Phenotype
  • Senotherapeutics

Substances

  • Senotherapeutics
  • Cytokines